Clinical trial
R115777 in Treating Patients With Refractory or Recurrent Acute Leukemia or…
NCT00004009 · University of Maryland, Baltimore, Other · Completed
Key facts
| NCT number | NCT00004009 |
|---|---|
| Title | R115777 in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia |
| Official title | A Phase I Study to Determine Biological Endpoints of Up to 21 Day Dosing of the Farnesyltransferase Inhibitor R115777 (IND# 52,302) for Refractory and Relapsed Adult Leukemias (Summary Last Modified 9/1999) |
| Lead sponsor | University of Maryland, Baltimore, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug |
| Interventions | tipifarnib |
| Start date | Jun 1, 1999 |
| Primary completion | Apr 1, 2001 |
| Completion | Apr 1, 2001 |
| First posted | Aug 27, 2004 |
| Last update posted | Nov 7, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: